The total number of activated CD103+ CD86+ and of CD103+ CD80+ cell subsets rose 10% and 12% by FACS, respectively, in the immune cells co-cultured with Poly(I:C)/INFα-treated-H460 cancer cells versus untreated H460 cells (Figure 5A). The gene discussed is CD80; the disease is cancer.